Ataraxis AI built a 5,000-patient model specifically for lobular cancer.
Public source
Publisher name
Public post
Lobular cancer comes up in nearly every conversation I have with med oncs, yet it gets <1% of dedicated research funding. What little data exists is mostly retrospective…
Company
Ataraxis AI
Transforming Cancer Care with AI Precision Medicine
- Industry
- Artificial Intelligence
- Location
- New York, US
- Company size
- 11–50 employees
About Ataraxis AI
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.
See moreLatest activity
Latest activity from Ataraxis AI
7 signals
Research & Knowledge
Ataraxis AI is launching Ataraxis ARC, a prospective study designed to evaluate AI model predictions and link them with real-world cancer patient outcomes, with initial enrollment of 1,000 patients across top cancer centers.
Research & Knowledge
Ataraxis AI is launching Ataraxis ARC, a prospective study designed to evaluate AI model predictions and link them with real-world cancer patient outcomes, with initial enrollment of 1,000 patients across top cancer centers.
Research & Knowledge
Ataraxis AI is launching a prospective registry study evaluating its AI prediction in more than just breast cancer.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
OncoGenomX
OncoGenomX published findings from 93 phase III and IV breast cancer trial manuscripts showing that 14.0 percent documented lobular inclusion at all.
Research & Knowledge
ArteraAI
ArteraAI VP of Medical Science Calvin Chao discussed how the ArteraAI Breast Test uses routine digital pathology slides and clinical information to provide risk stratification in approximately one hour.
Research & Knowledge
Cure51
Cure51 published a Rosalind Study combining multiple layers of patient data, including genomics, transcriptomics, pathology, clinical history, and multi-omics insights, to integrate complex datasets and identify patterns for AI-driven treatment prediction.
Research & Knowledge
IU Simon Comprehensive Cancer Center
IU Simon Comprehensive Cancer Center published a new article in Radiology titled Artificial Intelligence by Spyridon Bakas, PhD, and colleagues.
Research & Knowledge
Radiology News